Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

Organisation › Details

Boehringer Ingelheim Pharmaceuticals Inc.

	Start	1997-02-01 existent
	Group	Boehringer Ingelheim (Group)
	Industry	pharmaceutical

	Street	900 Ridgebury Road P.O. Box 368
	City	06877-0368 Ridgefiled, CT
	Tel	+1-203-798-9988
		Address record changed: 2018-07-24

Basic data	Employees	n. a.


		Record changed: 2018-10-31

More documents for Boehringer Ingelheim (Group)

[1] Boehringer Ingelheim. (10/29/19). "Press Release: Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing". Ingelheim....
[2] Biocat. (10/21/19). "Press Release: Boehringer Ingelheim Joins the d·HEALTH Barcelona Program to Foster Innovation in Health". Barcelona....
[3] Boehringer Ingelheim. (9/20/19). "Press Release: Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases". Ingelheim & Newton, MA....
[4] Boehringer Ingelheim. (9/4/19). "Press Release: Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound". Ingelheim & Mumbai....
[5] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
[6] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim Opens Health Management Centre in China". Shanghai....
[7] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies". Ingelheim....
[8] Boehringer Ingelheim. (7/18/19). "Press Release: INMARK Results Suggest Prompt Treatment of IPF with Antifibrotics to Slow Disease Progression". Ingelheim....
[9] Boehringer Ingelheim. (7/18/19). "Press Release: Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics". Ingelheim & Seongnam....
[10] Boehringer Ingelheim. (7/15/19). "Press Release: Boehringer Ingelheim Acquires Amal Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform". Ingelheim & Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]